Novo Nordisk A/S (NYSE:NVO) Stake Increased by Boston Family Office LLC

Boston Family Office LLC boosted its position in Novo Nordisk A/S (NYSE:NVO) by 3.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 44,524 shares of the company’s stock after buying an additional 1,280 shares during the period. Boston Family Office LLC’s holdings in Novo Nordisk A/S were worth $5,301,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of NVO. Natixis Advisors LLC lifted its stake in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares during the last quarter. Zions Bancorporation N.A. lifted its position in shares of Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after buying an additional 6,726 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after buying an additional 37,346 shares during the period. Private Wealth Partners LLC grew its position in shares of Novo Nordisk A/S by 155.1% during the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock valued at $3,953,000 after buying an additional 20,188 shares during the last quarter. Finally, Buckingham Capital Management Inc. acquired a new stake in Novo Nordisk A/S during the third quarter worth about $3,874,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on NVO shares. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Up 2.4 %

NVO stock opened at $105.06 on Monday. The firm’s 50-day moving average is $115.48 and its two-hundred day moving average is $128.81. The company has a market capitalization of $471.46 billion, a price-to-earnings ratio of 34.00, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.